TrialInternational journal of cancer2017
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.
Fariba Navid et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
39 papers cite it
this papertrialcites it